---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-291114"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2026-06-30T23:44:07+00:00"
generated_at: "2026-07-01T10:05:32.710348+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Aptose Biosciences acquired by Hanmi Pharmaceutical for C$2.41/share; shares to be delisted

## Summary
- Total consideration ~USD$3.47M for 2,043,719 shares not already owned by Hanmi.
- Premium of 28% over 30-day VWAP of C$1.88 on TSX.
- All directors resigned effective June 30, 2026.
- Common shares expected to be delisted from TSX on or about July 3, 2026.
- Company to terminate reporting obligations in US and Canada.

## SEC filing metadata
- accession: 0001193125-26-291114
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2026-06-30T23:44:07+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01, 3.03, 5.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000119312526291114/0001193125-26-291114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000119312526291114/d161768d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-291114
- JSON: https://secwatch.observer/filing/0001193125-26-291114.json
- Plain text: https://secwatch.observer/filing/0001193125-26-291114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.